Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 12/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delapril SCHEMBL34120 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL6511960 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL20840151 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725986 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725903 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL10533633 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL120907 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725914 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL28170907 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL1133648 | 0.98 | ACE (0.57) | ACEABCB11LMNAPDE3AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-03-31 | — | — | US | claimed |
| WO-2005016249-A2 | COMPOSITIONS OF A CHROMENE OR PHENYL ACETIC ACID CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ACE INHIBITOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-02-24 | — | — | WO | claimed |
| US-4822818-A | ANTIHYPERTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | claimed |
| EP-0051391-B1 | BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | claimed |
| EP-0051391-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-05-12 | — | — | EP | claimed |
| US-20100029734-A1 | METHODS FOR BREAST CANCER SCREENING AND TREATMENT | ORE PHARMACEUTICALS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009137543-A2 | METHODS FOR BREAST CANCER SCREENING AND TREATMENT | ORE PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2005079772-A2 | COMBINATION OF (S)-AMLODIPINE AND AN ACE INHIBITOR, AND METHODS FOR REDUCING HYPERTENSION | SEPRACOR INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-6610682-B2 | Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier | SANKYO COMPANY, LIMITED (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20020013308-A1 | Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier | SANKYO COMPANY LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| EP-1175902-A1 | Use of CS-866 (olmesartan) in the manufacture of a medicament for treating arteriosclerosis | Sankyo Company Limited (JP) | 2002-01-30 | — | — | EP | disclosed |
| EP-0930076-A1 | MEDICINAL COMPOSITIONS | SANKYO COMPANY LIMITED (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5098892-A | Angiotensin converting enzyme inhibitors as hypotensive agents | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-24 | — | — | US | disclosed |
| US-4831184-A | N-substituted-amido-amino acids | RORER PHARMACEUTICAL CORPORATION (US) | 1989-05-16 | — | — | US | disclosed |
| US-4822818-A | ANTIHYPERTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | disclosed |
| US-4686295-A | N-carboxy anhydride intermediates | USV PHARMACEUTICAL CORPORATION (US) | 1987-08-11 | — | — | US | disclosed |
| US-4474692-A | L-Alanyl-N-(indan-2-yl)glycine, its esters and salts thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0051391-B1 | BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | disclosed |
| EP-0051391-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013308-A1 | Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier | AGTR1, AGTR2, ACE | ACE 3/4885ABCB11 397/4885LMNA 543/4885 |
| US-20050070543-A1 | Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage | ACE, ACE2, AGTR2 | ACE 1/4885ABCB11 3191/4885LMNA 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.